Lobe Sciences Appoints Firms To Fund Psilocin Clinical Trials
16 Oct 2024 //
BUSINESSWIRE
Lobe Sciences, Alera Pharma Get US Patent For Conjugated Psilocin™
02 Oct 2024 //
BUSINESSWIRE
Lobe Sciences Announces Creation of Wholly Owned Subsidiary, Alera Pharma, Inc.
15 Aug 2024 //
BUSINESSWIRE
Lobe Sciences Appoints New Board And Executive Management Team
12 Aug 2024 //
BUSINESSWIRE
Lobe Sciences Announces Update
04 Jun 2024 //
BUSINESSWIRE
Wesley Ramjeet Joins Lobe Sciences Board With Financial Expertise
03 Jun 2024 //
BUSINESSWIRE
Lobe Sciences Announces Frederick D. Sancilio Ph.D. to Join Board of Directors
31 May 2024 //
BUSINESSWIRE
Dr Harry Jacobson, Ex-Merck And Vanderbilt, Joins Lobe Sciences Board
30 May 2024 //
BUSINESSWIRE
Lobe, Clearway Announce Change Of Control, Shareholder Value Focus
21 May 2024 //
BUSINESSWIRE
Lobe Sciences Provides Company Review of 2023
08 Jan 2024 //
BUSINESSWIRE
Lobe Sciences Provides Update on L-130 Clinical Program
07 Dec 2023 //
BUSINESSWIRE
Lobe Sciences, Ltd. Announces The Appointment Of Mathew Lee As CFO
18 Sep 2023 //
BUSINESSWIRE
Lobe Sciences, Ltd. Announces Amendment to the Acquisition of Altemia™ & Company
14 Sep 2023 //
BUSINESSWIRE
Lobe Sciences Appoints Baxter Phillips III, MBA as Chief Operating Officer
07 Jun 2023 //
BUSINESSWIRE
Lobe Sciences Announces Commercial Distribution Agreement With Pentec
17 May 2023 //
BUSINESSWIRE